InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
MWN-AI** Summary
InnoCare Pharma, a prominent biopharmaceutical company based in China, recently announced regulatory approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate clinical trials for ICP-538, a novel VAV1-directed molecular glue degrader (MGD). This approval marks a significant milestone, making ICP-538 the first VAV1 degrader to enter clinical trials in China and the second globally.
ICP-538 is a targeted therapeutic agent specifically designed to degrade the VAV1 protein, which plays a crucial role in the signaling pathways of T-cells and B-cells. This innovative treatment approach is aimed at addressing various autoimmune diseases, including inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. By promoting the degradation of the VAV1 protein, ICP-538 aims to effectively inhibit the proliferation, differentiation, and activation of T-cells, along with B-cell activation, thus exerting anti-inflammatory and immunomodulatory effects.
Preclinical studies have demonstrated that ICP-538 can significantly reduce cytokine levels associated with immune-mediated diseases without affecting other proteins, indicating high selectivity and minimal side effects. Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, emphasized the drug’s potential, highlighting its advantages of high target selectivity, multiple mechanisms of action, and substantial efficacy.
InnoCare focuses on discovering and developing innovative treatments for unmet medical needs in oncology and autoimmune diseases, boasting a strong presence in major Chinese cities and the United States. The company remains committed to advancing therapeutic options for patients facing challenging medical conditions.
MWN-AI** Analysis
InnoCare Pharma's recent announcement regarding the IND approval for ICP-538, a VAV1-directed molecular glue degrader, marks a significant milestone both for the company and the field of autoimmune disease treatments. This is especially pertinent as it is the first VAV1 degrader to enter clinical trials in China and the second globally, positioning InnoCare as a pioneer in this innovative therapeutic area.
Investors should assess the implications of this approval within the broader context of InnoCare’s strategic focus on unmet medical needs in cancer and autoimmune diseases. The targeted nature of ICP-538 gives it a potential competitive advantage, particularly since there are currently no approved therapies targeting VAV1. This exclusivity could lead to rapid market adoption if its clinical trials demonstrate efficacy and safety.
With preclinical studies suggesting significant therapeutic promise—including deep degradation of VAV1, reductions in pro-inflammatory cytokines, and a favorable safety profile—the groundwork is laid for optimistic outcomes in human trials. The anticipated success of ICP-538 could propel InnoCare’s stock and expand its market share significantly if it captures the interest of both healthcare professionals and investors.
However, potential investors should remain cautious. The biopharmaceutical landscape is fraught with challenges, including regulatory hurdles, the unpredictable nature of clinical trials, and competition from existing and emerging therapies. Additionally, the reliance on a single product for revenue generation, especially in a crowded market, adds a layer of risk.
In summary, while InnoCare’s IND approval positions it well for future growth, investors should adopt a balanced approach, weighing potential rewards against inherent risks associated with clinical development in the biopharmaceutical sector. Monitoring trial results and market dynamics will be key moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter clinical trials in China and the second globally.
ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors, for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. ICP-538 induces rapid and efficient degradation of VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. Currently, there are no approved VAV1-targeted therapies globally.
Degradation of VAV1 can effectively inhibit T-cell proliferation, differentiation, activation, and cytokine release, as well as B-cell activation and cytokine release, thereby exerting anti-inflammatory and immunomodulatory effects and alleviating autoimmune and inflammatory pathological processes. Preclinical studies have shown that ICP-538 induces deep degradation of VAV1, leading to a significant reduction in cytokines associated with immune-mediated diseases, with no detectable effects on other proteins.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “InnoCare has been developing novel drugs for the treatment of autoimmune diseases. As a novel targeted therapeutic agent, the VAV1 molecular glue degrader offers three major advantages: high target selectivity, mediation of multiple mechanisms of action, and high efficacy, which is expected to become a promising new therapeutic option for patients with autoimmune diseases.”
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
| Contact | |
| Media | Investors |
| Chunhua Lu | |
| 86-10-66609879 | 86-10-66609999 |
| chunhua.lu@innocarepharma.com | ir@innocarepharma.com |
FAQ**
How does InnoCare Pharma INCPF plan to differentiate ICP-538 from other potential VAV1-targeted therapies as the first VAV1 degrader approved for clinical trials in China?
What are the anticipated timelines for the clinical trials of ICP-538, and how will InnoCare Pharma INCPF ensure a thorough evaluation of its safety and efficacy in treating autoimmune diseases?
Can you elaborate on the specific autoimmune diseases ICP-5targets, and how does InnoCare Pharma INCPF plan to measure its impact on T-cell and B-cell activation in clinical trials?
Given the lack of approved VAV1-targeted therapies globally, how does InnoCare Pharma INCPF foresee the competitive landscape changing following the potential success of ICP-538 in clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about InnoCare Pharma (OTC: INCPF).
NASDAQ: INCPF
INCPF Trading
0.0% G/L:
$1.55 Last:
1,000 Volume:
$1.55 Open:
